Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Avigen, Targanta Make Deep Cuts

by Rick Mullin
January 5, 2009 | A version of this story appeared in Volume 87, Issue 1

Avigen will halt clinical trials on AV650, a neuromuscular treatment, and sell an early-stage developmental compound for hemophilia, AV513, to Baxter International for $7 million. The firm says it will concentrate on finding a partner to develop AV411, a neurologic pain treatment. The move, which follows poor clinical results for AV650, will eliminate 28 jobs, or 70% of Avigen's staff. Meanwhile, Targanta Therapeutics is cutting its workforce by 75% to 27 employees as it focuses on its lead candidate, oritavancin, a treatment for gram-positive skin infections. Staff reductions at both firms were expected to be completed by the end of December.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.